Kane, J, Honiigfeld, G, Singer, J, Meltzer, H.
Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry
1988; 45: 789–96.
Greenwood-Smith, C, Lubman, DI, Castle, DJ. Serum clozapine levels: a review of their clinical utility. J Psychopharmacol
2003; 17: 234–8.
Rostami-Hodjegan, A, Amin, AM, Spencer, EP, Lennard, MS, Tucker, GT, Flanagan, RJ, et al. J Clin Psychopharmacol
2004; 24: 70–8.
Taylor, D, Paton, C, Kapur, S.
The Maudsley Prescribing Guidelines in Psychiatry (11th edn). Wiley-Blackwell, 2012.
Therapeutic monitoring of antipsychotic drugs. CPD Clin Biochemistry
2006; 7: 3–18.
Spina, E, de Leon, J.
Metabolic drug interactions with newer antipsychotics: a comparative review. Bas Clin Pharmacol Toxicol
2007; 100: 4–22.
Chetty, M, Murray, M.
CYP-mediated clozapine interactions: How predictable are they?
Curr Drug Metabol
2007; 8: 307–13.
Urichik, L, Prior, TI, Dursun, S, Baker, G.
Metabolism of atypical antipsychotics: involvement of cytochrome P450 enzymes and relevance for drug-drug interactions. Curr Drug Metabol
2008; 9: 410–8.
Finch, CK, Chrisman, CR, Baciewicz, AM, Self, TH. Rifampin and rifabutin drug interactions: an update. Arch Int Med
2002; 162: 985–92.
Niemi, M, Backman, JT, Fromm, MF, Neuvonen, PJ, Kivisti, KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokin
2003; 42: 819–50.
Reitman, ML, Chu, A, Cai, X, Yabut, J, Venkatasubramanian, R, Zajic, S, et al. Rifampicin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Therap
2011; 89: 234–42.
Baciewicz, AM, Chrisman, CR, Finch, CK, Seif, TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin
2013; 29: 1–12.
Psychotropic Drug Directory: The Professionals' Pocket Handbook and Aide Memoire. Lloyd-Reinhold Communications, 2012.
Virani, A, Bezchlibnyk-Butler, KZ, Jeffries, JJ (eds) Clinical Handbook of Psychotropic Drugs (20 edn). Hogrefe & Huber, 2014.
Prior, TI, Chue, PS, Tibbo, P, Baker, GB. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol
1999; 9: 301–9.
Prior, TI, Baker, GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci
2003; 28: 99–112.
Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol
2006; 58: 871–85.
Spina, E, Scordo, MG, D'Arrigo, C.
Metabolic drug interactions with new psychotropic agents. Fund Clin Pharmacol
2003; 17: 517–38.
Joos, A, Udo, FG, Wolfgang, KP. Pharmacokinetic interaction of clozapine and rifamipicin in a forensic patient with a atypical mycobacterial infection?
J Clin Psychopharmacol
1998: 18: 83–5.
Peritogiannis, V, Pappas, D, Antoniou, K, Hyphantis, T, Mavreas, V.
Clozapine-rifampicin interaction in a patient with pulmonary tuberculosis. Gen Hosp Psychiatry
2007; 29: 280–2.
Panesar, N, Pai, N, Valachova, I.
Late onset neutropenia with clozapine. Austr N Z J Psychiatry
2011; 45: 684.
Public Health England. Collaborative Tuberculosis Strategy for England 2015 to 2020. Public Health England, 2015.
Naranjo, CA, Busto, U, Sellers, EM, Sandor, P, Ruiz, I, Roberts, EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Therapeut
1981; 30: 239–45.